Recent Updates
Recently added Catalysts

BIIB147

Phase 1/2

Amyotrophic Lateral Sclerosis | Small Molecules | Neurology |Biogen Inc.|Trials Updated: Nov 12, 2026

BIIB147 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment69

FDA Designations

No designations recorded

BIIB147 clinical trials

BIIB147 · 1 trial · 1 indication

Phase 1/2 1
NCT07855211A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis
RECRUITING69 Analytics
PHASE1/PHASE2RECRUITING
A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral SclerosisUnlock trial analytics

Study Endpoints

Primary Endpoints

MAD, OLE, Integrated MAD and OLE Periods: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Up to Week 416

Secondary Endpoints

MAD, OLE, Integrated MAD and OLE Periods: Serum Concentrations of Total Active BIIB147 Related Species
Pre-dose and at multiple time points post-dose [MAD: Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D); OLE and Integrated MAD and OLE: Up to Week 340
MAD, OLE, Integrated MAD and OLE Periods: Cerebrospinal Fluid (CSF) Concentrations of Total Active BIIB147 Related Species
Pre-dose at multiple timepoints [MAD: Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D); OLE and Integrated MAD and OLE: Up to Week 340]
MAD Period: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of BIIB147
Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
MAD: Cohort AEXPERIMENTALParticipants will either receive Dose A of BIIB147 or a placebo for 12 weeks.
MAD: Cohort BEXPERIMENTALParticipants will either receive Dose B of BIIB147 or a placebo for 12 weeks.
MAD: Cohort CEXPERIMENTALParticipants will either receive Dose C of BIIB147 or a placebo for 12 weeks.
MAD: Cohort DEXPERIMENTALParticipants will either receive Dose D of BIIB147 or a placebo for 20 weeks.
OLEEXPERIMENTALParticipants from Cohorts A-D who complete the MAD period will enter a 4-week blinded loading-dose period. During this period, participants randomized to BIIB147 in the MAD period will receive placebo, followed by BIIB147, while participants randomized to placebo during the MAD period will receive BIIB147. Upon completion of the blinded loading-dose period, all participants will enter the open-label maintenance dose period and receive BIIB147 for up to 340 weeks.

Interventions

NameTypeDescription
BIIB147DRUGAdministered intrathecally (IT)
PlaceboDRUGAdministered IT
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites3

Key Inclusion Criteria: MAD Period * Participants must have a diagnosis of ALS consistent with the Gold Coast criteria. * No pathogenic variants, likely pathogenic variants, or variants of uncertain significance in the superoxide dismutase 1 (SOD1) or fused in sarcoma (FUS) genes (confirmed by cen...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 12, 2026NCT07855211lastUpdatePostDate: changed
LOWNov 12, 2026NCT07855211lastUpdatePostDate: changed
LOWOct 26, 2026NCT07855211lastUpdatePostDate: changed
LOWOct 26, 2026NCT07855211lastUpdatePostDate: changed
LOWOct 19, 2026NCT07855211Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 19, 2026NCT07855211Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 19, 2026NCT07855211Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 2, 2026NCT07855211NEW_TRIAL: changed
LOWOct 2, 2026NCT07855211NEW_TRIAL: changed

Frequently asked questions about BIIB147

What is BIIB147 used for?

BIIB147 is an investigational small molecule being developed by Biogen for amyotrophic lateral sclerosis (ALS). It is in Phase 1 clinical development and is not approved for any use. The only study listed for BIIB147 enrolls adults with ALS in the United States.

Who makes BIIB147?

BIIB147 is being developed by Biogen Inc., which trades on Nasdaq under the ticker BIIB. Biogen is the sponsor of the Phase 1 study of BIIB147 in amyotrophic lateral sclerosis, which is currently recruiting participants in the United States.

What phase is BIIB147 in?

BIIB147 is in Phase 1 clinical development. It is an investigational small molecule for amyotrophic lateral sclerosis and is not approved by the FDA. One Phase 1 trial is currently recruiting, and no completed trials of BIIB147 are listed.

What clinical trials is BIIB147 in?

BIIB147 is being studied in one Phase 1 trial, NCT07855211, titled A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS). The trial is recruiting up to 69 adults aged 18 and older in the United States and is randomized, double-blind, and controlled.

Is BIIB147 tested in biomarker-selected patients?

Yes. The Phase 1 trial of BIIB147, NCT07855211, is biomarker-selected, meaning enrollment is guided by a biomarker. The study is randomized, double-blind, and controlled, and it enrolls adults with amyotrophic lateral sclerosis rather than healthy volunteers, with a planned enrollment of 69 participants.